Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.51 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GGT1 | P19440 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3616371 | 1.00 | GRM2 (0.51) | GRM2GRM3SMN1; SMN2HIF1ABLM | |
| SCHEMBL27748006 | 1.00 | GRM2 (0.51) | GRM2GRM3SMN1; SMN2HIF1ABLM | |
| Hydrochloric Acid SCHEMBL1807415 | 0.98 | GRM2 (0.50) | GRM2GRM3SMN1; SMN2HIF1ABLM | |
| Hydrochloric Acid SCHEMBL31587976 | 0.98 | GRM2 (0.50) | GRM2GRM3SMN1; SMN2HIF1ABLM | |
| SCHEMBL692989 | 0.89 | GRM2 (0.54) | GRM2GRM3SMN1; SMN2HIF1ABLM | |
| Hydrochloric Acid SCHEMBL15372829 | 0.87 | GRM2 (0.52) | GRM2GRM3SMN1; SMN2HIF1ABLM | |
| SCHEMBL9190217 | 0.87 | GRM2 (0.46) | GRM2GRM3SMN1; SMN2HIF1AALDH1A1 | |
| SCHEMBL23177172 | 0.86 | LTB4R (0.54) | GRM2GRM3SMN1; SMN2HIF1APOLB | |
| SCHEMBL16468979 | 0.86 | LTB4R (0.54) | GRM2GRM3SMN1; SMN2HIF1APOLB | |
| SCHEMBL31563005 | 0.85 | BLM (0.69) | BLMALDH1A1GGT1SLC6A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1544 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085582-A1 | PROTEIN CAGES | THE UNIVERSITY OF SYDNEY (AU) | 2026-04-30 | — | — | WO | disclosed |
| US-20260069728-A1 | MULTI-TARGETING COMPOUND AND USE THEREOF | CHENGDU SHETAI MEDICAL TECHNOLOGY CO., LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| US-20250319054-A1 | Synthetic Eicosanoid Analogues for the Treatment and Prevention of Diseases Associated with Increased GDF15 Plasma Concentration | OMEICOS THERAPEUTICS GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| EP-4627079-A2 | THERMOSTABLE BINDING SCAFFOLDS | Nectagen, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | disclosed |
| EP-4590664-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | OMEICOS THERAPEUTICS GMBH (DE) | 2025-07-29 | — | — | US | disclosed |
| CN-120202191-A | Inhibitors of prostate specific membrane antigen and uses thereof | 上海先通生物科技有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4551563-A2 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS, INC. (US) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025091087-A1 | BISPECIFIC PROTEINS | MONASH UNIVERSITY (AU) | 2025-05-08 | — | — | WO | disclosed |
| WO-1997025344-A1 | CLIP ANALOGUES AND AUTOIMMUNE DISEASE | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1997-07-17 | — | — | WO | disclosed |
| WO-1997023501-A1 | THERAPEUTIC COMPOSITIONS | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997016202-A1 | CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997015663-A1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997012037-A1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-04-03 | — | — | WO | disclosed |
| WO-1997005257-A1 | PEPTIDE ANALOG INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
| WO-1997004091-A1 | NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-02-06 | — | — | WO | disclosed |
| EP-0672049-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994011388-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319054-A1 | Synthetic Eicosanoid Analogues for the Treatment and Prevention of Diseases Associated with Increased GDF15 Plasma Concentration | IL15, ALOX15, FABP3 | GRM2 1725/4885GRM3 688/4885SMN1; SMN2 1813/4885 |
| US-20260069728-A1 | MULTI-TARGETING COMPOUND AND USE THEREOF | CXCR4, CXCR2, GRPR | GRM2 134/4885GRM3 176/4885SMN1; SMN2 1134/4885 |
| US-20250263393-A1 | FAP INHIBITORS | FAP, APC, FIBP | GRM2 4842/4885GRM3 4867/4885SMN1; SMN2 722/4885 |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | ALOX5, ALOX15B, ALOX15 | GRM2 2435/4885GRM3 1291/4885SMN1; SMN2 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.